

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Essential thrombocythemia | D013920 | — | D47.3 | 1 | 2 | — | — | — | 2 |
| Polycythemia vera | D011087 | — | D45 | 1 | 2 | — | — | — | 2 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | 2 | — | — | — | 2 |
| Thrombocytosis | D013922 | — | D75.83 | 1 | 2 | — | — | — | 2 |
| Polycythemia | D011086 | EFO_0005804 | D75.1 | 1 | 2 | — | — | — | 2 |
| Drug common name | NS-018 |
| INN | ilginatinib |
| Description | Ns-018 is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against tyrosine-protein kinase JAK2. In addition, it is known to target non-receptor tyrosine-protein kinase TYK2, tyrosine-protein kinase JAK3, and tyrosine-protein kinase JAK1. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | 1239358-85-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545217 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 56R994WX4L (ChemIDplus, GSRS) |